Abera Bioscience AB reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was SEK 0.306 million compared to SEK 0.178 million a year ago. Net loss was SEK 1.94 million compared to SEK 0.457 million a year ago. Basic loss per share from continuing operations was SEK 0.18 compared to SEK 0.07 a year ago. Diluted loss per share from continuing operations was SEK 0.18 compared to SEK 0.07 a year ago.
For the nine months, revenue was SEK 0.769 million compared to SEK 0.653 million a year ago. Net loss was SEK 6.55 million compared to SEK 1.76 million a year ago. Basic loss per share from continuing operations was SEK 0.65 compared to SEK 0.25 a year ago. Diluted loss per share from continuing operations was SEK 0.65 compared to SEK 0.25 a year ago.